2. Search Result
Search Result
Results for "

action potential duration

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

1

Peptides

2

Natural
Products

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0747
    Oxypeucedanin

    		Potassium Channel Apoptosis Cardiovascular Disease Cancer
    Oxypeucedanin is a furocoumarin derivative isolated from Angelica dahurica. Oxypeucedanin is a selective open-channel blocker, inhibits the hKv1.5 current with an IC50 value of 76 nM. Oxypeucedanin prolongs cardiac action potential duration (APD), is a potential antiarrhythmic agent for atrial fibrillation . Oxypeucedanin induces cell apoptosis through inhibition of cancer cell migration .
    Oxypeucedanin
  • HY-N0747R
    Oxypeucedanin (Standard)

    		Potassium Channel Apoptosis Cardiovascular Disease Cancer
    Oxypeucedanin (Standard) is the analytical standard of Oxypeucedanin. This product is intended for research and analytical applications. Oxypeucedanin is a furocoumarin derivative isolated from Angelica dahurica. Oxypeucedanin is a selective open-channel blocker, inhibits the hKv1.5 current with an IC50 value of 76 nM.?Oxypeucedanin prolongs cardiac action potential duration (APD), is a potential antiarrhythmic agent for atrial fibrillation . Oxypeucedanin induces cell?apoptosis through inhibition of cancer cell migration .
    Oxypeucedanin (Standard)
  • HY-17504AS
    Rosuvastatin-d3

    ZD 4522 d3

    		 Isotope-Labeled Compounds HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Cardiovascular Disease Metabolic Disease
    Rosuvastatin-d3 is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM[1]. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals[2].
    Rosuvastatin-d3
  • HY-17504A
    Rosuvastatin

    ZD 4522

    		 HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin
  • HY-120926
    BBR 2160

    		Calcium Channel Others
    BBR 2160 is a compound with cardiac electrophysiological effects and is a dihydropyridine calcium antagonist that can reduce myocardial contractility and action potential duration and has calcium antagonist properties.
    BBR 2160
  • HY-106682
    Falipamil

    AQ-A 39

    		 Calcium Channel Cardiovascular Disease
    Falipamil (AQ-A 39), a calcium channel blocker, is a bradycardic agent. The bradycardic effect results from a reduction in the diastolic depolarization rate and a prolongation of the action potential duration .
    Falipamil
  • HY-113841
    RS-87337

    		Others Cardiovascular Disease
    RS-87337 is an orally active antiarrhythmic agent that increases the duration and the maximum rate of rise of cardiac muscle action potentials. RS-87337 is promising for research of antiarrhythmic and cardioprotective agents .
    RS-87337
  • HY-137986
    LUF7244

    		Potassium Channel Inflammation/Immunology
    LUF7244 is a selective allosteric modulator of Kv11.1 channels. LUF7244 inhibits early afterdepolarizations. LUF7244 can be used for anti-arrhythmia research .
    LUF7244
  • HY-165524
    AM 92016

    		Potassium Channel Cardiovascular Disease
    AM 92016 is a potassium channel blocker. AM 92016 can increase the duration of action potentials in isolated ventricular cells from guinea pigs and rabbits. AM 92016 has proarrhythmic activity in guinea pigs and pigs .
    AM 92016
  • HY-116478
    L-3373

    		Potassium Channel Others
    L-3373 is a voltage-dependent potassium channel inhibitor with activity that reduces the effective refractory period and the dispersion of monophasic action potential duration, while significantly reducing susceptibility to ventricular fibrillation in a cat model of left ventricular hypertrophy.
    L-3373
  • HY-12533
    Disopyramide
    1 Publications Verification

    Dicorantil; SC-7031

    		 Sodium Channel Potassium Channel Cardiovascular Disease
    Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide
  • HY-12533A
    Disopyramide phosphate
    1 Publications Verification

    Dicorantil phosphate; SC-7031 phosphate

    		 Potassium Channel Sodium Channel Cardiovascular Disease
    Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide phosphate
  • HY-12533B
    Disopyramide hydrochloride

    Dicorantil hydrochloride; SC-7031 hydrochloride

    		 Sodium Channel Potassium Channel Cardiovascular Disease
    Disopyramide hydrochloride is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide hydrochloride blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide hydrochloride inhibits HERG encoded potassium channels. Disopyramide hydrochloride also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide hydrochloride
  • HY-B0615A
    Moricizine Hydrochloride

    EN 313; Ethmozin; Moracizine

    		 Others Cardiovascular Disease
    Moricizine Hydrochloride (EN 313) is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period .
    Moricizine Hydrochloride
  • HY-W010950A
    Flecainide hydrochloride
    2 Publications Verification

    		 Potassium Channel Sodium Channel Cardiovascular Disease
    Flecainide hydrochloride is a potent and orally active antiarrhythmic agent. Flecainide hydrochloride blocks the cardiac fast inward Na + current (INa) and the rapid component of the delayed rectifier K + current. Flecainide hydrochloride prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide hydrochloride has the potential for the research of fetal tachycardias .
    Flecainide hydrochloride
  • HY-W010950
    Flecainide
    2 Publications Verification

    		 Potassium Channel Sodium Channel Cardiovascular Disease
    Flecainide is a potent and orally active antiarrhythmic agent. Flecainide blocks the cardiac fast inward Na + current (INa) and the rapid component of the delayed rectifier K + current. Flecainide prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide has the potential for the research of fetal tachycardias .
    Flecainide
  • HY-130456
    AHR 10718

    		Others Cardiovascular Disease
    AHR 10718 is an antiarrhythmic agent that suppresses cardiac arrhythmias induced by digitalis intoxication and myocardial infarction in the intact dog. AHR 10718 also depresses membrane responsiveness and conduction, shortens the effective refractory period of specialized conducting fibers less than action potential duration .
    AHR 10718
  • HY-126028A
    (+)-Sotalol

    (S)-Sotalol

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease
    (+)-Sotalol ((S)-Sotalol) is the S-isomer of Sotalol (HY-103196). Sotalol is an orally active, non-selective β-adrenergic receptor blocker. (+)-Sotalol is an antiarrhythmic agent. (+)-Sotalol can prolong action potential duration in isolated cardiac muscle .
    (+)-Sotalol
  • HY-111245
    AZD-1305

    		Potassium Channel Calcium Channel Sodium Channel Cardiovascular Disease Neurological Disease
    AZD-1305 is an antiarrhythmic agent and atrial selective sodium channel/potassium channel blocker, which can significantly prolongs action potential duration and reduces excitability, cause atrial selective ERP prolongation and acute termination of atrial fibrillation. AZD1305 can be used for atrial fibrillation research .
    AZD-1305
  • HY-12533R
    Disopyramide (Standard)

    		Sodium Channel Potassium Channel Cardiovascular Disease
    Disopyramide (Standard) is the analytical standard of Disopyramide. This product is intended for research and analytical applications. Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide (Standard)
  • HY-W010950R
    Flecainide (Standard)

    		Potassium Channel Sodium Channel Cardiovascular Disease
    Flecainide (Standard) is the analytical standard of Flecainide. This product is intended for research and analytical applications. Flecainide is a potent and orally active antiarrhythmic agent. Flecainide blocks the cardiac fast inward Na + current (INa) and the rapid component of the delayed rectifier K + current. Flecainide prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide has the potential for the research of fetal tachycardias .
    Flecainide (Standard)
  • HY-118148
    UK-66914

    		Potassium Channel Cardiovascular Disease
    UK-66914, is a class III antiarrhythmic agent that specifically acts on the delayed rectifier potassium current (I_K). UK-66914 is designed to prolong action potential duration (APD) and increase cardiac refractory period, thereby potentially terminating the reentry mechanism in arrhythmias without affecting the serious side effects of antiarrhythmic drugs associated with other ion channels such as Na+ and Ca2+ currents .
    UK-66914
  • HY-136995
    AFD-21 maleate

    		Others Cardiovascular Disease
    AFD-21 maleate is a drug with antiarrhythmic activity. AFD-21 maleate inhibits sodium channels by binding to sodium channels in an inactive state, with both use-dependent and voltage-dependent effects. The unbinding rate of AFD-21 maleate is similar to that of Class I antiarrhythmic drugs with moderate kinetics. AFD-21 maleate can cause a slight prolongation of the action potential duration and significantly reduce the maximum rise rate of the action potential at certain concentrations. AFD-21 maleate also showed use-dependent blocking effects as stimulation frequency increased .
    AFD-21 maleate
  • HY-B0615AS
    Moricizine-d8(Hydrochloride)

    EN 313-d8; Ethmozin-d8; Moracizine-d8

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Moricizine-d8 (Hydrochloride) is the deuterium labeled Moricizine Hydrochloride (HY-B0615A). Moricizine Hydrochloride is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period[1][2].
    Moricizine-d8(Hydrochloride)
  • HY-14924
    Inakalant

    		Potassium Channel Cardiovascular Disease
    Inakalant is an atrial specific potassium channel blocker with antiarrhythmic activity. Inakalant works by selectively blocking potassium channels in heart cells, thereby prolongs the action potential duration (APD) of cardiomyocytes and increases the effective refractory period of the atria and ventricles, which helps to terminate and prevent the occurrence of arrhythmias such as atrial fibrillation (AF). Inakalant can be used in the study of arrhythmia and cardiac electrophysiology .
    Inakalant
  • HY-118317
    Zacopride

    		Endogenous Metabolite Cardiovascular Disease
    Zacopride is a selective agonist with the activity of enhancing the inward rectifier potassium current (IK1) in rabbit hearts. Zacopride also exhibits significant antiarrhythmic effects, inhibiting ventricular arrhythmias by increasing IK1 without affecting atrial arrhythmias. Zacopride can hyperpolarize the resting membrane potential and shorten the action potential duration (APD) in a concentration-dependent manner. Zacopride significantly reduced the incidence of compound-induced early afterdepolarizations (EADs) at 1 μmol/L .
    Zacopride
  • HY-108591
    L-364,373

    R-L3

    		 Potassium Channel Cardiovascular Disease
    L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates Iks (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes .
    L-364,373
  • HY-W779529
    Cerberin

    2'-Acetylneriifolin

    		 Others Cancer
    Cerberin is a cardiac glycoside that has been found in C. odollam and has cytotoxic and cardiac modulatory activities. It is cytotoxic to KB and NCI H187 cancer cells (IC50s=1.92 and 1.24 μg/mL).1 Cerberin inhibits Na+/K+-ATPase, increasing intracellular sodium levels and action potential duration in cardiac cells.
    Cerberin
  • HY-108204
    AZD 3043

    THRX 918661

    		 Others Others
    AZD 3043 (THRX 918661) is a positive allosteric modulator of GABA(A) receptors with sedative and hypnotic activity. AZD 3043 can enhance GABA(A) receptor-mediated chloride currents in vitro and produce hypnotic and electroencephalographic inhibitory effects in vivo. Due to its esterase-dependent metabolic pathway, it has a short duration of action and can be quickly cleared even after long-term infusion, which may have clinical application potential.
    AZD 3043
  • HY-107036
    BMS-394136

    		Potassium Channel Cardiovascular Disease
    BMS-394136 (compound 1) is a potent inhibitor of Kv 1.5, with an IC50 of 0.05 μM. BMS-394136 is a selective IKur inhibitor. BMS-394136 dose-dependently prolongs atrial effective refractory period (AERP) and action potential duration (APD) without effecting ventricular effective refractory period (VERP). BMS-394136 can be used for acute atrial ischemia research .
    BMS-394136
  • HY-120026
    KB130015

    KB015

    		 Thyroid Hormone Receptor Neurological Disease
    KB130015 (KB015) is an orally active and potent ThRα and ThRβ (Thyroid Hormone Receptor) inhibitor, with IC50 values of 4.5 and 5.1 μM, respectively. KB130015 has antiarrhythmic properties. KB130015 markedly slows the kinetics of inactivation of Na + channels. KB130015 opens large-conductance Ca 2+-activated K + channels and relaxes vascular smooth muscle .
    KB130015
  • HY-17504B
    Rosuvastatin Sodium
    Maximum Cited Publications
    14 Publications Verification

    ZD 4522 Sodium; X-Plended Sodium; Crestor Sodium

    		 HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Sodium
  • HY-17504BS2
    Rosuvastatin-13C,d3 sodium

    ZD 4522-13C,d3 sodium; X-Plended-13C,d3 sodium; Crestor-13C,d3 sodium

    		 Autophagy Bacterial HMG-CoA Reductase (HMGCR) Potassium Channel Isotope-Labeled Compounds Cardiovascular Disease Metabolic Disease
    Rosuvastatin- 13C,d3 sodium is 13C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin-13C,d3 sodium
  • HY-107719
    D-AP7

    		iGluR Neurological Disease
    D-AP7 is a specific NMDA receptor antagonist with inhibitory activity against epileptiform activity. D-AP7 attenuated neuronal activation in spot activity by reducing the duration and number of exogenously induced bursts. D-AP7 also increased the amplitude of secondary action potentials, which may restore neuronal activity in some epileptiform bursts. D-AP7 showed anxiogenic effects and impaired memory consolidation in passive avoidance learning .
    D-AP7
  • HY-P4742A
    6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) (TFA)

    6-FAM-AEEAC-SHK TFA

    		 Biochemical Assay Reagents Potassium Channel Neurological Disease
    6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA (6-FAM-AEEAC-SHK TFA) is a peptide neurotoxin conjugated with a fluorescent marker. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can block voltage-gated potassium channels (kv1.1 and kv1.2) to prolong the duration of action potentials, thereby affecting the conduction of neural signals. 6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) TFA can be used in neuroscience research .
    6-FAM-AEEAc-Stichodactyla helianthus Neurotoxin (ShK) (TFA)
  • HY-17504
    Rosuvastatin Calcium
    Maximum Cited Publications
    14 Publications Verification

    Rosuvastatin hemicalcium; ZD 4522 Calcium

    		 HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Calcium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: